Floatz logo

Blinatumomab

Leukemia, B-cell

Children's Hospital Medical Center, Cincinnatimonoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Leukemia, B-cell cohort.

Asset / SponsorPhaseRating
Fludarabine
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Ibrutinib
Loxo Oncology, Inc.
Phase 4BBB
Busulphan
Dartmouth-Hitchcock Medical Center
Phase 4BB
Pirtobrutinib
Loxo Oncology, Inc.
Phase 3BB
cc-5013
University of Wisconsin, Madison
Phase 2BB

View all 50 →

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →
Precursor B-Cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →